Author:
Lang Wenwang,Deng Lian,Huang Bei,Zhong Dongmei,Zhang Gaofeng,Lu Meijun,Ouyang Ming
Publisher
Springer Science and Business Media LLC
Reference37 articles.
1. Jiang L, Zhao N, Xu M, Pei J, Lin Y, Yao Q, et al. Incidence of primary liver cancer in different geographical regions of China from 1978 to 2012 and projections to 2032: an age-period-cohort analysis. Int J Cancer. 2024;154(3):465–76. https://doi.org/10.1002/ijc.34724. (Epub 2023/9/14).
2. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.
3. Wang RH, Hu M, Yang ZY, Niu ZY, Chen HS, Zhou X, et al. Global liver cancer incidence and mortality and future trends from 2000 to 2020: GLOBOCAN data analysis. Zhonghua Gan Zang Bing Za Zhi. 2023;31(3):271–80.
4. Rumgay H, Arnold M, Ferlay J, Lesi O, Cabasag CJ, Vignat J, et al. Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol. 2022;77(6):1598–606.
5. Galle PR, Finn RS, Qin S, Ikeda M, Zhu AX, Kim TY, et al. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial. Lancet Oncol. 2021;22(7):991–1001.
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献